Assessment of the Levodopa-Induced Dyskinesia (LID) Pipeline, 2020 - ResearchAndMarkets.com

The "Levodopa-Induced Dyskinesia (LID) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Levodopa-Induced Dyskinesia (LID) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Levodopa-Induced Dyskinesia (LID) market. A detailed picture of the Levodopa-Induced Dyskinesia (LID) pipeline landscape is provided, which includes the disease overview and Levodopa-Induced Dyskinesia (LID) treatment guidelines.

The assessment part of the report embraces in-depth Levodopa-Induced Dyskinesia (LID) commercial assessment and clinical assessment of the Levodopa-Induced Dyskinesia (LID) pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Levodopa-Induced Dyskinesia (LID) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

• All of the companies that are developing therapies for the treatment of Levodopa-Induced Dyskinesia (LID) with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Levodopa-Induced Dyskinesia (LID) treatment.
• Levodopa-Induced Dyskinesia (LID) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Levodopa-Induced Dyskinesia (LID) market.

Scope of the Report

• The Levodopa-Induced Dyskinesia (LID) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Levodopa-Induced Dyskinesia (LID) across the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of Levodopa-Induced Dyskinesia (LID) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
• Detailed Levodopa-Induced Dyskinesia (LID) research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Levodopa-Induced Dyskinesia (LID).

Key Topics Covered

1. Report Introduction

2. Levodopa-Induced Dyskinesia (LID)

2.1. Overview

2.2. History

2.3. Levodopa-Induced Dyskinesia (LID) Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Levodopa-Induced Dyskinesia (LID) Diagnosis

2.6.1. Diagnostic Guidelines

3. Levodopa-Induced Dyskinesia (LID) Current Treatment Patterns

3.1. Levodopa-Induced Dyskinesia (LID) Treatment Guidelines

4. Levodopa-Induced Dyskinesia (LID) - Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Levodopa-Induced Dyskinesia (LID) companies collaborations, Licensing, Acquisition - Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Levodopa-Induced Dyskinesia (LID) Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Levodopa-Induced Dyskinesia (LID) Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Levodopa-Induced Dyskinesia (LID) Late Stage Products (Phase-III)

7. Levodopa-Induced Dyskinesia (LID) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Levodopa-Induced Dyskinesia (LID) Discontinued Products

13. Levodopa-Induced Dyskinesia (LID) Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

14. Levodopa-Induced Dyskinesia (LID) Key Companies

15. Levodopa-Induced Dyskinesia (LID) Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Levodopa-Induced Dyskinesia (LID) Unmet Needs

18. Levodopa-Induced Dyskinesia (LID) Future Perspectives

19. Levodopa-Induced Dyskinesia (LID) Analyst Review

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

Companies Mentioned

• VistaGen Therapeutics, Inc.
• Prilenia
• Zambon S.p.A.
• Prexton Therapeutics

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/y3sizp

View source version on businesswire.com: https://www.businesswire.com/news/home/20200703005079/en/